Lenalidomidă Dr. Reddy’s

Lenalidomide, the active ingredient in Lenalidomidă Dr. Reddy’s, is an immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomidă Dr. Reddy’s as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, clinics and procurement teams worldwide, with EU‑GMP‑certified manufacturing and full regulatory documentation.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone‑marrow clones. - Multiple myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic syndromes (MDS): reduces transfusion dependence and delays transformation to acute leukemia. - Mantle cell lymphoma: enhances response when combined with other agents in relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue - Diarrhea - Rash - Low blood counts (neutropenia, anemia)

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Severe neutropenia leading to infection - Secondary primary malignancies

Before initiating therapy, clinicians should evaluate several safety considerations. - Pregnancy: contraindicated; use effective contraception and confirm negative pregnancy test before initiating therapy. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation when risk factors are present. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia, anemia or thrombocytopenia. - Renal impairment: adjust dosing and monitor renal function in patients with reduced clearance. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Lenalidomide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) – may markedly reduce exposure. - Anticoagulants (warfarin) – increased risk of bleeding; requires close INR monitoring. - Immunosuppressants (e.g., cyclosporine) – may enhance toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole) – may increase plasma levels. - P‑glycoprotein substrates (e.g., digoxin) – potential for altered concentrations. - Live attenuated vaccines – risk of reduced efficacy or infection.